IJIRR

International Journal of Information Research and Review
Vol. 12, Issue, 01, pp.7909-7919, January, 2025

RESEARCH ARTICLE

EFFECTS OF A METAL-CURCUMIN COMPLEX ON ACETIC ACID INDUCED ULCERATIVE COLITIS IN RATS: ROLE OF OXIDATIVE STRESS AND TNF-α

Abhishek Joshi[1,2*], Shubham Lehene[1,3] and Arun Soni[4] and Sanjeev Acharya[5]

[1]Research scholar, SSR College of Pharmacy, Department of Pharmacology, Sayli, Silvassa, 396230, Union Territory of Dadra and Nagar Haveli and Daman and Diu, India; [2]Department of Pharmacology, Dr. Chunibhai Vallabbhai Patel College of Pharmacy, Uka Tarsadia University, Maliba Campus, Bardoli-394601, Gujarat, India; [3] Meril Healthcare Pvt. Ltd., Vapi, 396191, India; [4]Faculty of Pharmacy, Ramanbhai Patel College of Pharmacy, CHARUSAT Campus, Changa, Gujarat- 388421, India; [5]Institute of Pharmacy, Ganpat University, Mehsana-384012, Gujarat, India

ARTICLE INFO

Article History:
Received 18th October, 2024
Received in revised form
24th November, 2024
Accepted 25th December, 2024
Published online 30th January, 2025

Key words:

Inflammatory Bowel Disease, Ulcerative Colitis, Crohn's Disease, Curcumin, Metal Curcumin Complex.

ABSTRACT

Ulcerative colitis, often known as UC, is an inflammatory bowel disease (IBD) that affects the lining of the colon and rectum and can lead to irritation, inflammation, and ulceration in these areas. Curcumin forms complexes with metal ions. Previous research has shown that combining a metal with curcumin improves its pharmacological effect. In the current study, a metal curcumin complex (MCC) was synthesized using sodium. Its efficacy in treating an ulcerative colitis model caused by acetic acid in Sprague Dawley rats was assessed.Sprague Dawley rats were given an intracolonic injection of 4% v/v acetic acid to induce colitis. Following induction, the rats were given either saline (0.9% v/v), MCC (30, 50, and 100 mg/kg), or curcumin (100 mg/kg) once a day for six days. Weight, stool consistency, and rectal bleeding were observed throughout the six days. On the seventh day, using cervical dislocation and diethyl ether, animals were sacrificed.Each animal's blood was collected, and the serum was separated for biochemical assessment. The colon of each animal was excised, and observed was macroscopical damage. The serum that was isolated following blood collection was tested for cytokine levels. The colon tissue homogenate was used for the biochemical study of oxidative stress parameters. Treatment with MCC demonstrates considerable protection against UC, proven by a significant decrease in the DAI and colonic damage compared to acetic acid-induced colitis rats. In the MCC and curcumin-treated groups, the depleted levels of catalase (CAT), superoxide dismutase (SOD), and reduced glutathione (GSH) were significantly restored. At the same time, the enhanced lipid peroxidation (LPO) and myeloperoxidase (MPO) were significantly decreased. MCC dramatically reduced the activation of the TNF-alpha pathway in colon tissues, as seen by lower TNF-α levels in MCC-treated rats.

Copyright © 2025, Abhishek Joshi et al. *This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution and reproduction in any medium, provided the original work is properly cited.*

INTRODUCTION

Ulcerative colitis (UC) and Crohn's disease (CD)are two chronically recurrent inflammatory disorders of the gastrointestinal tract (GI) tract. They are both referred to as inflammatory bowel disease (IBD). UC usually affects the colon, but CD can affect any part of the GI tract. Ulcerative colitis is a relapsing condition that causes irritation, inflammation, and ulceration of the colon and rectum lining. It is identified by mucosal injury and ulcerations(1).Various variables may influence ulcerative colitis, including intestinal dysbiosis, genetic disorders, immune system disruptions, environmental factors, and lifestyle habits(2). Severe illnesses like colorectal cancer can develop due to chronic infection(3). UC was previously reported to be more widespread in developed nations; however, in recent years, it has been discovered that the frequency seems higher in Asian countries but has not yet acquired the exact prevalence as in Western hemisphere countries (4). Because the symptoms of experimentally produced UC in animals closely resemble those that occur in people, these animal models are being used in scientific research to understand the disease's numerous pathophysiological pathways better and look for potential treatments (5). But in addition to the different in vivo experimental animal models, several in vitro and ex vivo systems have also been developed that closely imitate ulcerative colitis and resemble the human gut. These are superior to ulcerative colitis animal models (6). The increased production of prostaglandins and leukotrienes is the most prevalent pathological consequence linked with UC(7).The involvement of oxidative stress in the onset of ulcerative colitis has also been supported by earlier research (8–10).An altered colonic environment mainly influences the pathophysiology of IBD, atypical mucosal glycosaminoglycan, impaired oxidation

of short-chain fatty acids, increased intestinal permeability, and sulfide generation (11). Anti-TNF-α antibodies (infliximab), sulphasalazine, corticosteroids, azathioprine, and methotrexate are extensively used medications for the treatment of UC. These aim to control the mucosa's complications, disease relapse, and inflammation(12,13). The drug is selected based on the disease's consequences, extent, and severity, as well as the patient's reaction to current or previous treatment(14). Unfortunately, the current treatments are ineffective because they need prolonged usage and might cause drug intolerance, adverse drug responses, and allergic reactions. As a result, plant medications may be an alternative for treating UC. Due to their low cost, few side effects, and continued widespread acceptance, plant-based medications and their natural products may be an alternative for treating ulcerative colitis (15). There have been a significant number of studies published so far that demonstrate the impact of various plants and the chemical components of those plants on ulcerative colitis(1,16–20).

Curcumin, an Indian spice, has been used extensively in Ayurvedic medicine for ages due to its non-toxicity and multiple therapeutic characteristics, such as anti-inflammatory, antioxidant, analgesic, and antiseptic capabilities(21). Numerous studies have indicated that curcumin has anti-cancer, hypocholesterolemic, wound-healing, anticoagulant, hepatoprotective, antibacterial, and antispasmodic properties (22–26). Curcumin is a yellow-colored chemical component derived from the rhizomes of the *Curcuma longa* plant. Curcumin has a notable role in ulcerative colitis because it modifies the inflammatory response by suppressing the activity of the enzymes inducible nitric oxide synthase (iNOS), lipoxygenase, and cyclooxygenase(27–29). Even though there is a lot of evidence that curcumin has pharmacological effects, its low solubility and bioavailability make it hard to know how to get the best therapeutic results(30). Because of its low solubility and poor oral bioavailability, curcumin's application in the prevention and treatment of human diseases has been severely restricted. Curcumin is unstable at neutral and basic pH values, which is also the cause of the negative pharmacokinetics of this molecule, therefore in addition to solubility and bioavailability issues, this molecule also suffers from instability in the gastrointestinal tract (31–33). Researchers have developed potential delivery systems and approach in recent years to increase curcumin's stability, bioavailability, and water solubility(30).Through chelation, curcumin has a remarkable capacity to form complexes with metal ions. Metal-curcumin complexes have attracted much attention in recent years due to their success in addressing the abovementioned issues. Compared to curcumin alone, metal curcumin complexes have a more profound impact on diseases (34–38).In previous studies, the sodium metal-curcumin complex has anti-inflammatory and anti-diarrheal properties (39–41). In the current research, we have synthesized a metal curcumin complex and investigated its ameliorative effect on acetic acid-induced ulcerative colitis in Sprague Dawley rats.

MATERIALS AND METHODS

Chemicals and Reagents: Curcumin 95% (1*E*,6*E*)-1,7-bis(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione) was purchased from NatBiome Speciality Healthcare Pvt Ltd (Gandhinagar, India). Sodium chloride and sodium hydroxide was purchased from Research-Lab Fine Chem (Mumbai, India). Ellman's reagent (5,5-dithio-bis-(2-nitrobenzoic acid) was purchased from Research-Lab Fine Chem (Mumbai, India). Hexadecyl trimethyl ammonium bromide (hexadecyl (trimethyl) azanium; chloride) was purchased from Yarrowchem Products (Mumbai, India). o-Dianisidine (4-(4-amino-3-methoxyphenyl)-2-methoxyaniline) was procured fromRamagundam Fertilizers and Chemicals Limited (New Delhi, India). All other compounds used in the study were of the analytical grade and were procured from Sigma-Aldrich Company (St. Louis, MO, USA).

Synthesis of a metal-curcumin complex: The metal-curcumin complex (MCC) was synthesized using a method proposed by Peni *et al*. (42). 250mg of curcumin was dissolved in 30mL of ethanol, previously mixed with 25mg of solid NaOH (sodium hydroxide), which was then reacted with 20mg of NaCl (sodium chloride). The resultant mixture was then subjected to reflux for 2-3 hours until the color changed to deep red. The schematic prediction of the reaction of sodium metal precursor with curcumin is shown in Figure 1.



Fig.1. Schematic prediction of the reaction of sodium metal precursor with curcumin

Characterization of MCC

Thin Layer Chromatography: The metal curcumin complex was analysed using thin layer chromatography with precoated silica gel 60 F254 aluminium plates (2 x 4 cm) serving as the stationary phase. The mobile phase used was a mixture of chloroform: ethanol: glacial acetic acid (9.5: 0.4: 0.1). After air drying, the developed chromatographic plate was examined with UV light (254 and 365 nm). Calculated R_f values were compared to curcumin Rf values (43).

UV-visible Spectroscopy: UV-visible spectroscopy of MCC and curcumin was performed on a UV-vis spectrophotometer (Agilent Cary 60). Samples were scanned in the range of 200-800 nm and absorbance v/s concentration was performed.

Solubility studies: Equilibrium solubility method was utilized to perform the solubility studies of MCC.In conical flasks, excess MCC was added to 25 mL of 0.1 N HCl (pH 1.2), phosphate buffer (pH 6.8), and phosphate buffer (pH 7.4). These flasks were placed in solubility shaker at 37°C. After 12 h, all solutions were filtered and analysed using a UV spectrophotometer at 466 nm against 0.1 N HCl (pH 1.2), phosphate buffer (pH 6.8), and (pH 7.4). The solubilized amount of drug was then calculated.

Animal care: Female Sprague-Dawley rats weighing 100-150 g were procured from the animal house facility of Zydus Lifesciences Ltd, Ahmedabad, India. Individual propylene cages were used to house all the animals. The animals were fed with commercial NPD (regular protein diet) pellets and were given free access to water. Animals were maintained under controlled environmental conditions (20-25°c, 50-55%

humidity, and 12hr light/dark cycle). Before beginning the study, animals were acclimatized for seven days. Experiments on animals were carried out following protocols approved by the SSR College of Pharmacy, Institutional Animal Ethics Committee (IAEC) and found to be in accordance with the provision of the Committee for the Purpose of Control and Supervision of Experiments on Animals (CPCSEA) guidelines for laboratory animal facility.

Acute toxicity study: The OECD (Organization for Economic Co-operation and Development) guideline 420 for the testing of chemicals was followed for conducting an acute oral toxicity study(44). Four groups of six rats each were formed by randomly assigned the animals. The first group, the control group, was given unlimited access to food and purified water. The three other groups received a single oral dosage of 500, 1000, or 2000 mg/kg b.w. MCC. All rats were closely monitored for any unusual behavior during the first four hours, and the number of rats perished was noted after 24 hours. Each animal was then monitored for 14 days to look for toxicity, behavioral abnormalities, and symptoms of impending death. All the animals were anesthetized with diethyl ether before the experiment and then euthanized through cervical dislocation. The removal of internal organs was done, and they were examined for toxicity.



Fig. 2. Experimental Design

Experimental Design: The experimental design is shown in the figure 2. Thirty-six healthy female rats were randomly divided into six groups containing six rats in each group (n=6). They were then subjected to acclimatization for seven days.

Group 1 (Control)- Intracolonic administration of saline (0.9% v/v NaCl)
Group 2 (A.A control)- Intracolonic administration of 1-2 ml 4%v/v acetic acid

Group 3 (Cur 100 + A.A)- 100 mg/kgb.w curcuminorally
Group 4 (MCC 30 + A.A)- 30 mg/kg b.w MCC orally
Group 5 (MCC 50 + A.A)- 50 mg/kg b.w MCC orally
Group 6 (MCC 100 + A.A)- 100 mg/kg b.w MCC orally

For six days, Group 1 received saline daily. Acetic acid (1-2 ml, 4% v/v) was intrarectally administered to the animals in groups 2 to 6. After induction, a treatment regimen using curcumin and MCC was initiated and followed for six days. Weight, stool consistency, and rectal bleeding were observed throughout the six days. On the seventh day, using cervical dislocation and diethyl ether, animals were sacrificed. Each animal's blood was collected, and the serum was separated for biochemical assessment. The colon of each animal was excised, and observed was macroscopical damage.

Induction of Colitis: Ulcerative colitis may be readily and reproducibly caused by administering 1-2 mL of 4 percent v/v acetic acid intrarectally for 30 seconds (45). Pentobarbital sodium (30 mg/kg i.p.) was used to anesthetize the rats. A polyethylene catheter was placed approximately 8 cm into the anus for rectal administration. Each rat was maintained in the Trendelenburg posture for 30 seconds before being rinsed with saline to neutralize the acid's harshness.

Assessment of Disease Activity Index (DAI): The clinical severity of colitis was evaluated by noting changes in growth rate, stool consistency, and the presence of bleeding and occult blood in stools. Each day, these were graded on a scale of 0 to 4 (Table 1). The DAI was measured using the Cooper *et al.* grading system (46).

Table 1. Scoring of DAI

Score	Decrease in growth%	Stool Consistency	Rectal Bleeding
0	0	Normal	Normal
1	1-5	Normal	+
2	5-10	Loose stools	++
3	10-15	Loose stools	+++
4	>15	Diarrhea	Gross bleeding

The disease activity index can be calculated according to the following formula:

$$DAI=\frac{\text{\% Body weight loss score+Diarrohea score+Rectal score}}{3} \quad (1)$$

Assessment of colon damage by macroscopic scoring: Using the grading system outlined by Wallace *et al.*(47), colonic ulceration and inflammation were evaluated. From the proximal end to the anus, a colonic segment of approximately 8 cm was separated. Following that, a longitudinal incision was made in each separated colon tissue. The colon tissue lesion was graded using the scale in Table 2.

Table 2 Criteria for scoring of ulceration and inflammation

Score	Appearance
0	Normal
1	Localized hyperaemia, no ulcers
2	Ulceration without hyperaemia or bowel wall thickening
3	Ulceration with inflammation at one site
4	Two or more sites of ulceration
5	Major sites of damage extending >1 cm along length of colon
6-10	Area of damage extended >2 cm along length of colon, score was increased by 1 for each additional cm of involvement.

Assessment of cytokine level (serum TNF-α): Blood was drawn from each animal and allowed to clot for 1 hour before being centrifuged for 20 minutes at 1000xg at 2-8^{0}C. The separated serum was utilized to test the cytokine (TNF-α). The serum was tested for colonic TNF-α using an enzyme-linked immunosorbent assay (ELISA) kit, as directed by the manufacturer (Elabscience Biotechnology Inc., United States).

Preparation of Tissue Homogenates: After cervical dislocation, colon tissues were removed from each animal group and washed in cold saline.



Fig. 3. UVspectra of metal- curcumin complex (A) and curcumin (B)



*p<0.05, **p<0.01, and ***p<0.001, ****p<0.0001 comparison of acetic acid control group to the control group; #p<0.05, ##p<0.01, and ###p<0.001, ####p<0.0001 comparison of Cur (100), MCC (30), MCC (50), MCC (100) with acetic acid control group; $p<0.05, $$p<0.01, $$$p<0.001, $$$$p<0.0001 comparison of MCC (30), MCC (50), MCC (100) with Cur (100) group. The data are expressed as mean ± standard deviation (n=6).

Fig. 4 Effect of MCC on % growth rate of body weight (A) and DAI (B) in acetic acid induced colitis



A: Control; B: Acetic acid colitis control; C: Curcumin (100 mg/kg) + colitis; D: MCC (30 mg/kg) + colitis; E: MCC (50 mg/kg) + colitis; F: MCC (100 mg/kg) + colitis

Fig. 5. Effect of MCC on gross anatomy of colon in acetic acid induced colitis

Table 3. Comparison of solubility of MCC and curcumin

Sr. No.	pH	Solubility (mcg/ml)	
		MCC	Curcumin
1	7.4	169 ± 0.75	3.34 ± 0.19
2	6.8	58.4 ± 0.49	1.2 ± 0.14
3	1.2	42.4 ± 1.62	0.8 ± 0.06

Each tissue was homogenized using a tissue homogenizer (Remilabworld, India) after being manually minced. In cooled phosphate buffer, a 10 percent tissue homogenate was produced (0.1M, pH 7.4). The tissue homogenates were centrifuged for 10 minutes at 700xg and 40 degrees Celsius to remove debris. The recovered supernatant was employed for testing various parameters.

Assessment of Myeloperoxidase (MPO) activity: 0.1 ml of supernatant was combined with 2.9 ml of 50 mM phosphate buffer, pH 6, containing 0.167 mg/ml O-dianisidine hydrochloride and 0.0005% hydrogen peroxide. The change in absorbance at 460 nm was measured with a UV-Visible spectrophotometer. Myeloperoxidase activity was described as the weight of wet colon tissue's U/g (units/gram). The procedure previously described by Janice *et al*. (48)was used to determine the MPO levels in tissue homogenates. It was calculated by using the following formula:

MPO activity (U/g)= X/weight of the piece of tissue taken. (2)

Where X= 10 x change in absorbance per min/ volume of supernatant taken in the final concentration

Assessment of Superoxide dismutase (SOD) activity: SOD activity was measured using the method previously described by Marklund *et al*. with slight modifications (49). 0.1M potassium phosphate buffer (pH 7.4) was mixed with a 0.2 ml sample. To this solution, 0.2 ml of previously prepared pyrogallol solution was added. Pyrogallol solution was prepared by dissolving 2.6 mM pyrogallol solution in 10mM HCl. Immediately after the 30s, the absorbance of the mixture was taken at 325 nm. SOD activity was reported as U/mg protein. The following formula was used to assess the activity:

Unit of SOD/mL of sample = [(A-B) x 100]/A x 50 (3)

Where, A = change in absorbance per minute of standard,
B= change in absorbance per minute of the test sample.

Assessment of Reduced glutathione (GSH) activity: Colonic reduced glutathione (GSH) levels were analyzed using the Ellman method (50). In brief, 0.02 mL DTNB (0.1 M in Phosphate buffer pH 7.0), 3 mL homogenate, phosphate buffer 2 mL, water 5 mL were added, and absorbance was taken at 412 nm after 2 minutes. The reduced GSH level was calculated using the following formula:

A = a.b.c
(a = 0.017 $mM^{-1}cm^{-1}$) (4)

Assessment of Catalase activity: Catalase was estimated by the procedure described by Hugo Aebi (51). In 2 mL of tissue homogenate, 1 mL of H2O2 (30 mM in 50 mM of Phosphate buffer pH 7.0) was added, and absorbance was taken at 240 nm with 30-sec intervals. Catalase activity was calculated using the following equation. The result was expressed as nano moles of H_2O_2 consumed/minute/mg protein.

$$\text{Catalase activity} = \frac{\frac{\Delta A}{\text{minute}} \times \text{total volume of assay}}{0.81 \times \text{sample volume} \times \text{mg of protein}} \quad (5)$$

Assessment of Lipid peroxidase (LPO) activity: To determine the degree of lipid peroxidation, the amount of malondialdehyde (MDA) in the colon homogenates was utilized (52). In 0.2 mL of homogenate, 0.2 mL of 8.1% SDS, 1.5 mL of 20% acetic acid solution adjusted to pH 3.5 with NaOH, and 1.5 mL of 0.8% aqueous solution of TBA were added. The combination was prepared to a volume of 4 mL using distilled water and heated for 60 minutes in an oil bath at 95 °C. After cooling, 5 mL of the n butanol/pyridine (15:1, v/v) mixture and 1 mL of distilled water were added and rapidly shaken. The organic layer was removed, and its absorbance at 532 nm was measured after centrifugation at 4000 rpm for 10 minutes. The results were represented in nanomoles per mg of protein. The LPO activity was calculated according to the following formula:

A= a.b.c (6)

a= 1.56×10^{-5}

Statistical Analysis: One-way analysis of variance (ANOVA) followed by post hoc Tukey's test was used to compare the different groups with the disease group and/or control group. Statistical significance was considered if $p<0.05$. The analysis was performed using GraphPad Software (version 8.0.2).

RESULTS

Characterization of MCC: Thin layer chromatography of MCC and curcumin was performed using a mixture of chloroform : ethanol : glacial acetic acid (9.5 : 0.4 : 0.1). The R_f value of MCC was found to be 0.92 ± 0.01, whereas that of curcumin was 0.96 ± 0.01. UV spectra of curcumin and MCC are depicted in the figure3. It shows that both have λ_{max}value equal to 425 nm.

Solubility studies: Solubility studies of MCC and curcumin were performed using equilibrium solubility method and was found that MCC was more soluble than curcumin alone (Table 3).

Acute toxicity study: MCC was shown to be safe at all three of the tested dosages. Throughout the study, no indicators of death or toxicity were recorded. So, for further in vivo research, dosages of 30, 50, and 100 mg/kg b.w were chosen following the toxicity test conducted on MCC.

Effect of MCC on Disease Activity Index (DAI): The extent and severity of the colitis induced by acetic acid administration were evaluated in all of the animals. Acetic acid-induced colitis in rats exhibited a marked decrease ($p<0.001$) in body weight, as shown in figure 4(A).



*p<0.05, **p<0.01, and ***p<0.001, ****p<0.0001 comparison of acetic acid control group to the control group; #p<0.05, ##p<0.01, and ###p<0.001, ####p<0.0001 comparison of Cur (100), MCC (30), MCC (50), MCC (100) with acetic acid control group; \$p<0.05, \$\$p<0.01, \$\$\$p<0.001, \$\$\$\$p<0.0001 comparison of MCC (30), MCC (50), MCC (100) with Cur (100) group. The data are expressed as mean ± standard deviation (n=6).

Fig.6 Effect of MCC on macroscopical ulcer score



*p<0.05, **p<0.01, and ***p<0.001, ****p<0.0001 comparison of acetic acid control group to the control group; #p<0.05, ##p<0.01, and ###p<0.001, ####p<0.0001 comparison of Cur (100), MCC (30), MCC (50), MCC (100) with acetic acid control group; \$p<0.05, \$\$p<0.01, \$\$\$p<0.001, \$\$\$\$p<0.0001 comparison of MCC (30), MCC (50), MCC (100) with Cur (100) group. The data are expressed as mean ± standard deviation (n=6).

Fig.7 Effect of MCC on serum TNF-α levels in acetic acid induced colitis



*p<0.05, **p<0.01, and ***p<0.001, ****p<0.0001 comparison of acetic acid control group to the control group; #p<0.05, ##p<0.01, and ###p<0.001, ####p<0.0001 comparison of Cur (100), MCC (30), MCC (50), MCC (100) with acetic acid control group; \$p<0.05, \$\$p<0.01, \$\$\$p<0.001, \$\$\$\$p<0.0001 comparison of MCC (30), MCC (50), MCC (100) with Cur (100) group.The data are expressed as mean ± standard deviation (n=6).

Fig. 8 . Effect of MCC on myeloperoxidase activity in acetic acid induced colitis



*p<0.05, **p<0.01, and ***p<0.001, ****p<0.0001 comparison of acetic acid control group to the control group; #p<0.05, ##p<0.01, and ###p<0.001, ####p<0.0001 comparison of Cur (100), MCC (30), MCC (50), MCC (100) with acetic acid control group; \$p<0.05, \$\$p<0.01, \$\$\$p<0.001, \$\$\$\$p<0.0001 comparison of MCC (30), MCC (50), MCC (100) with Cur (100) group. The data are expressed as mean ± standard deviation (n=6).

Fig. 9. Effect of MCC on superoxide dismutase activity in acetic acid induced colitis

However, MCC treatment in colitis rats resulted in a significant increase in the % growth rate of body weights compared to the control and curcumin-treated rats. From figure4(A), it is also clear that 100 mg/kg b.w MCC was able to significantly increase the % growth rate of the body compared to the same dose of curcumin (100 mg/kg b.w).

The DAI score is a significant indicator to assess the colonic injury, from signs such as decreased bodyweight, diarrhea, and rectal bleeding. The lower DAI score is considered as the animal is closer to the normal physiological state.

In the present study, acetic acid-induced colitis rats exhibited symptoms of UC, as indicated by diarrhea and bloody stools. DAI scores of the disease control groups were higher than those of the other groups (figure4B). A decrease (p<0.0001, p<0.0001) in the DAI was observed by MCC at doses 50 and 100 mg/kg as compared to the curcumin-treated group. But the marked decrease in the DAI score was observed at the dose 100 mg/kg b.w of MCC.

Effect of MCC on colon damage (macroscopical scoring): Colon tissues of the control group exhibited typical intact



*p<0.05, **p<0.01, and ***p<0.001, ****p<0.0001 comparison of acetic acid control group to the control group; #p<0.05, ##p<0.01, and ###p<0.001, ####p<0.0001 comparison of Cur (100), MCC (30), MCC (50), MCC (100) with acetic acid control group; $p<0.05, $$p<0.01, $$$p<0.001, $$$$p<0.0001 comparison of MCC (30), MCC (50), MCC (100) with Cur (100) group. The data are expressed as mean ± standard deviation (n=6).

Fig.10 Effect of MCC on reduced glutathione in acetic acid induced colitis

*p<0.05, **p<0.01, and ***p<0.001, ****p<0.0001 comparison of acetic acid control group to the control group; #p<0.05, ##p<0.01, and ###p<0.001, ####p<0.0001 comparison of Cur (100), MCC (30), MCC (50), MCC (100) with acetic acid control group; $p<0.05, $$p<0.01, $$$p<0.001, $$$$p<0.0001 comparison of MCC (30), MCC (50), MCC (100) with Cur (100) group. The data are expressed as mean ± standard deviation (n=6).

Fig.11 Effect of MCC on catalase activity in acetic acid induced colitis



***p<0.05, **p<0.01, and ***p<0.001, ****p<0.0001 comparison of acetic acid control group to the control group; #p<0.05, ##p<0.01, and ###p<0.001, ####p<0.0001 comparison of Cur (100), MCC (30), MCC (50), MCC (100) with acetic acid control group; $p<0.05, $$p<0.01, $$$p<0.001, $$$$p<0.0001 comparison of MCC (30), MCC (50), MCC (100) with Cur (100) group. The data are expressed as mean ± standard deviation (n=6).**

Fig.12. Effect of MCC on lipid peroxidase activity in acetic acid induced colitis

structure with no lesions or hyperemia (figure 5 A). The colonic specimens of acetic acid control rats appeared ulcerated, edematous, and hemorrhagic (figure 5 B). Treatment of rats with curcumin (100 mg/kg) and MCC(30, 50, and 100 mg/kg) significantly restored the visible injuries produced by acetic acid (figure 5 C-F). The extent of colon damage was assessed using previously mentioned criteria (table 2). All animals were evaluated using this ulcer severity scoring. The macroscopical ulcer score was found to be significantly (p<0.0001) increased in colitis control; however, treatment of MCC 50 mg/kg and 100 mg/kg showed a significant decrease (p<0.01) in the damage to the colon as compared to curcumin-treated group (Figure 6).

Effect of MCC on cytokine level (serum TNF-α): The TNF-α levels (pg/ml) were found to be significantly (p<0.001) increased in the acetic acid control group, as depicted in figure 7.Curcumin (p<0.05) and MCC (p<0.0001) both showed a significant decrease in the levels of serum TNF-α against the acetic acid control group. Whereas MCC 30 mg/kg(p<0.01), 50 mg/kg (p<0.001), and 100 mg/kg (p<0.0001) were found to be significant in decreasing the TNF- α levels when compared to the curcumin-treated group.

Effect of MCC on Myeloperoxidase (MPO) activity: The results of the treatment of MCC on acetic acid-induced colitis are depicted in figure 8. There was a significant ($p<0.0001$) increase in the MPO activity acetic acid control compared to the control group. Curcumin-treated and MCC-treated groups both showed a significant ($p<0.0001$) decrease in the MPO activity compared to the acetic acid control group. While comparing MCC groups with curcumin, it was found that MCC (30 and 100 mg/kg) showed a significant ($p<0.0001$) decrease in the MPO activity.

Effect of MCC on Superoxide dismutase (SOD) activity: The acetic acid induction caused a significant ($p<0.0001$) decrease in the levels of superoxide dismutase enzyme compared to the control group. However, from Figure 9, it is clear that treatment of curcumin and MCC caused a significant increase ($p<0.0001$) in the activity of SOD compared to acetic acid control. It can also be depicted that a dose of 100 mg/kg MCC was able to increase the SOD activity when compared to the curcumin-treated group ($p<0.05$).

Effect of MCC on Reduced glutathione (GSH) activity: Figure 10 shows that the intracolonic administration of acetic acid significantly ($p<0.0001$) decreased the reduced glutathione levels compared to the control group. Curcumin treatment significantly ($p<0.01$) increased the reduced glutathione activity compared to the acetic acid control group. MCC 100 mg/kg ($p<0.0001$) showed marked improvement in the reduced glutathione activity compared with the acetic acid control group. When compared to curcumin-treated groups, MCC (100 mg/kg) showed a significant ($p<0.0001$) increase in the reduced GSH activity.

Effect of MCC on Catalase activity: Compared to the control group, a significant ($p<0.0001$) decrease in the catalase activity was observed in the acetic acid-induced colitis group. Curcumin treated group and MCC treated group (50 and 100 mg/kg) both were able to increase significantly ($p<0.05$, $p<0.001$, $p<0.0001$, respectively) the catalase activity when compared to the acetic acid control group. From figure 11, it is clear that MCC at 100 mg/kg b.w dose was able to significantly ($p<0.05$) increase the catalase activity compared to the curcumin-treated group.

Effect of MCC on Lipid peroxidase (LPO) activity: Figure 12 shows that compared to the control group, there was a significant ($p<0.0001$) increase in lipid peroxidase activity when rats were treated with intracolonic administration of acetic acid. Treatment of curcumin (100 mg/kg) and MCC (30, 50, and 100 mg/kg b.w) led to a significant ($p<0.0001$) decrease in the LPO activity compared to the acetic acid control group. MCC at the doses 30 and 100 mg/kg were able to significantly ($p<0.01$, $p<0.05$ respectively) decrease the LPO activity compared to that of the curcumin-treated group.

DISCUSSION

Due to its non-toxicity and several beneficial properties, including its antimicrobial, analgesic, antioxidant, and anti-inflammatory properties, curcumin has been utilized widely in Ayurvedic medicine for centuries (21). The pharmacological effects of curcumin are well documented, yet due to its hydrophobic nature, it has a low water solubility and bioavailability (30–33). Several researchers have developed new techniques to increase curcumin's bioavailability and solubility. Metal-curcumin complexes are one such technique that has garnered interest (30).The previous study suggests that metal-curcumin complexes have been employed successfully against various diseases in animal models (53). Still, the attempt to investigate its usage in the treatment of ulcerative colitis is unclear.The present study investigated the ameliorative effect of metal-curcumin complex (MCC) against acetic acid-induced UC in Sprague Dawley rats. By administering 4% acetic acid rectally to Sprague Dawley rats, colitis was caused. They had symptoms and indications that were similar to those of colitis patients, including bloody diarrhoea, diarrhoea, and a loss of body weight, which is consistent with earlier research (54). This investigation showed that MCC considerably reduced the degree of acetic acid-induced colonic impairment. The synthesized metal curcumin complex (MCC) was characterized by TLC and UV-visible spectroscopy. The results of TLC (R_f value) of MCC (0.92 0.01) compared to curcumin alone (0.96 0.01) showed the formation of the metal complex. A change in absorbance was observed in case of UV – visible spectra of MCC.

According to the findings of solubility tests (table 3), the complexation of curcumin with metal enhances its solubility across all pH ranges. A disease activity index (DAI) score can determine the severity of acetic acid-induced colitis. Weight loss might reflect the extent of intestinal inflammation(54).Increased cytokines like TNF-α and IL-6 have been linked to considerable weight loss in colitis due to the production of appetite-suppressing neuropeptides (55). In the present research, intrarectal administration of acetic acid resulted in a significant reduction in body weight, which may have been caused by symptoms of lack of appetite, malabsorption, and severe fluid loss due to rectal bleeding and diarrhea. However, administration of MCC (100 mg/kg b.w.) to rats with colitis significantly increased the weight gain rate. The DAI scores increased significantly in the acetic acid control groups, presumably due to severe edema and inflammatory cell infiltration (56). However, treatment of rats with colitis with MCC at doses of 50 and 100 mg/kg b.w. resulted in a substantial reduction in the DAI score compared to treatment with curcumin. This demonstrates that MCC has a better protective effect against acetic acid-induced colitis than curcumin.

TNF-α, a cytokine that promotes inflammation, is primarily thought to play a role in inflammatory diseases. According to findings, TNF-alpha is reported to be higher in the blood, stool samples, and mucosa of UC patients(57). Regulation of proinflammatory cytokines (TNF-α, IL-6, etc.) could be a realistic approach for treating UC(58,59).Acetic acid induces significant epithelial damage by releasing protons inside the epithelia's intracellular space. It raises levels of cytokines like TNF-α and IL-6 (60).Serum TNF-α levels were substantially higher in the acetic acid control group in the current study, correlating with previous findings (61). Both curcumin and MCC significantly reduced serum TNF-alpha levels compared to the acetic acid control group. However, MCC at all three doses (30, 50, and 100 mg/kg b.w.) demonstrated a substantial reduction in serum TNF-alpha compared to the curcumin-treated group.

Thus suggesting that MCC ameliorated acetic acid-induced colitis better than curcumin by significantly reducing serum TNF-α levels. One of the primary contributing causes to an inflammatory illness is oxidative stress and inhibited antioxidant defence mechanisms since these systems control the generation of reactive oxygen species (ROS)(8–10). According to the previous study, MPO and MDA levels are significantly elevated in inflammatory conditions such as ulcerative colitis (62,63). The findings are consistent with the current investigation, in which MDA and MPO levels in colon tissue homogenates were dramatically increased. Comparing the MCC and curcumin treatment groups to the acetic acid control group showed that both treatments significantly reduced MPO levels. MCC (30 and 100 mg/kg b.w.) showed a substantial reduction in the MPO levels compared to the curcumin group. Other antioxidants, such as SOD, reduced GSH, and catalase, is significantly reduced in an inflammatory state(64,65). The enzyme activities of SOD, reduced GSH, and catalase was considerably lower in the acetic acid control groups in the current study. The current study's findings corroborate the prior study's findings.Accordingly, the findings suggest that MCC was able to mitigate mucosal damage by lowering the levels of MDA and MPO and increasing levels of reduced GSH, SOD, and catalase in the colon tissues of colitis rats.

The acetic acid-induced colitis model is one of the study's limitations. We intend to test the colon protective effect of MCC on a more sophisticated model of ulcerative colitis, the dextran sodium sulfate-induced model because it will extract more information about innate immunity, and a more precise mechanism of pathogenesis can be deduced. Another limitation of the current study is the lack of precise characterization of the metal-curcumin complex (MCC), which will lead to a molecular-level approach to understanding its mechanism of disease amelioration, which will be reflected in our future research. We also aim to incorporate histological examination into our future investigations.

CONCLUSION

The current study is an initial effort to examine the metal-curcumin complex's (MCC) ameliorative impact against the acetic acid-induced model of UC. The results show that MCC reduced the severity and extent of colitis in rats via regulating TNF-α release and antioxidant levels, which had a protective impact on the mucosa. The findings also indicated that MCC had more significant potential for treating ulcerative colitis than curcumin. The results shown here consequently suggest that MCC has the potential to treat UC and will, hopefully, be explored in the future as a candidate for ulcerative colitis.

Acknowledgement: Not applicable

Code availability: Not applicable

Author contributions: AS designed research, AJ and SL performed the different activities and tests. AS and AJ analyzed the data. AJ wrote the manuscript. All authors read and approved the manuscript. SA gave final approval to the manuscript submission. The authors declare that all data were generated in-house and that no paper mill was used.

Data availability: Not applicable

Funding: The present research did not receive any funding.

Compliance with ethical standards

Conflict of interest: The authors declare that they have no conflicts of interest

Ethics approval: IAEC (Institutional Animal Ethics Committee) approved the experimental protocol SSR/IAEC/2021/029

REFERENCES

1. Li C, Wang J, Ma R, Li L, Wu W, Cai D, *et al*. Natural-derived alkaloids exhibit great potential in the treatment of ulcerative colitis. Pharmacological Research. 2022 Jan 1;175:105972.
2. Galipeau HJ, Caminero A, Turpin W, Bermudez-Brito M, Santiago A, Libertucci J, *et al*. Novel Fecal Biomarkers That Precede Clinical Diagnosis of Ulcerative Colitis. Gastroenterology. 2021;160(5):1532–45.
3. Kommuru S, Aziz SN, Sagireddy S, Kaur G, Rijal S, Loh CC, *et al*. Risk Factors for Colorectal Cancer in Inpatients With Ulcerative Colitis: A Nationwide Cross-Sectional Analysis. Cureus. 2022;14(7).
4. Ooi CJ, Hilmi I, Banerjee R, Chuah SW, Ng SC, Wei SC, *et al*. Best practices on immunomodulators and biologic agents for ulcerative colitis and Crohn's disease in Asia. Intest Res. 2019 Jul;17(3):285–310.
5. Low D, Nguyen DD, Mizoguchi E. Animal models of ulcerative colitis and their application in drug research. Drug Des Devel Ther. 2013 Nov 12;7:1341–57.
6. Joshi A, Soni A, Acharya S. In vitro models and ex vivo systems used in inflammatory bowel disease. In vitro models [Internet]. 2022 Apr 25; Available from: https://doi.org/10.1007/s44164-022-00017-w
7. Stoyanova II, Gulubova MV. Mast cells and inflammatory mediators in chronic ulcerative colitis. Acta Histochemica. 2002 Jan 1;104(2):185–92.
8. Amirshahrokhi K. Acrylamide exposure aggravates the development of ulcerative colitis in mice through activation of NF-κB, inflammatory cytokines, iNOS, and oxidative stress. Iran J Basic Med Sci. 2021 Mar;24(3):312–21.
9. Elmaksoud HAA, Motawea MH, Desoky AA, Elharrif MG, Ibrahimi A. Hydroxytyrosol alleviate intestinal inflammation, oxidative stress and apoptosis resulted in ulcerative colitis. Biomedicine & Pharmacotherapy. 2021 Oct 1;142:112073.
10. Mandlik DS, Mandlik SK, Patel S. Protective effect of sarsasapogenin in TNBS induced ulcerative colitis in rats associated with downregulation of pro-inflammatory mediators and oxidative stress. null. 2021 Sep 3;43(5):571–83.
11. Molodecky NA, Kaplan GG. Environmental risk factors for inflammatory bowel disease. Gastroenterol Hepatol (N Y). 2010 May;6(5):339–46.
12. Sales-Campos H, Basso PJ, Alves VBF, Fonseca MTC, Bonfá G, Nardini V, *et al*. Classical and recent advances in the treatment of inflammatory bowel diseases. Braz J Med Biol Res. 2015 Feb;48(2):96–107.

13. Jeong DY, Kim S, Son MJ, Son CY, Kim JY, Kronbichler A, *et al*. Induction and maintenance treatment of inflammatory bowel disease: A comprehensive review. Autoimmun Rev. 2019 May;18(5):439–54.
14. Hanzel J, Hulshoff MS, Grootjans J, D'Haens G. Emerging therapies for ulcerative colitis. null. 2022 May 4;18(5):513–24.
15. Gupta M, Mishra V, Gulati M, Kapoor B, Kaur A, Gupta R, *et al*. Natural compounds as safe therapeutic options for ulcerative colitis. Inflammopharmacology. 2022 Apr 1;30(2):397–434.
16. Akkol EK, Karpuz B, Sobarzo-Sánchez E, Khan H. A phytopharmacological overview of medicinal plants used for prophylactic and treatment of colitis. Food and Chemical Toxicology. 2020 Oct 1;144:111628.
17. Guo B, Bian Z, Qiu H, Wang Y, Wang Y. Biological and clinical implications of herbal medicine and natural products for the treatment of inflammatory bowel disease. Annals of the New York Academy of Sciences. 2017;1401(1):37–48.
18. Niu W, Chen X, Xu R, Dong H, Yang F, Wang Y, *et al*. Polysaccharides from natural resources exhibit great potential in the treatment of ulcerative colitis: A review. Carbohydrate Polymers. 2021;254:117189.
19. Irving PM, Iqbal T, Nwokolo C, Subramanian S, Bloom S, Prasad N, *et al*. A randomized, double-blind, placebo-controlled, parallel-group, pilot study of cannabidiol-rich botanical extract in the symptomatic treatment of ulcerative colitis. Inflammatory bowel diseases. 2018;24(4):714–24.
20. Billerey-Larmonier C, Uno JK, Larmonier N, Midura AJ, Timmermann B, Ghishan FK, *et al*. Protective effects of dietary curcumin in mouse model of chemically induced colitis are strain dependent. Inflamm Bowel Dis. 2008 Jun;14(6):780–93.
21. Zhou H, S Beevers C, Huang S. The targets of curcumin. Current drug targets. 2011;12(3):332–47.
22. Elbadawy M, Hayashi K, Ayame H, Ishihara Y, Abugomaa A, Shibutani M, *et al*. Anti-cancer activity of amorphous curcumin preparation in patient-derived colorectal cancer organoids. Biomedicine & Pharmacotherapy. 2021;142:112043.
23. Riyad P, Purohit A, Sen K, Ram H. Atherosclerotic plaque regression and HMG-CoA reductase inhibition potential of curcumin: An integrative omics and in-vivo study. Journal of Applied Biology and Biotechnology. 2022;10(1):1–3.
24. Fahimirad S, Abtahi H, Satei P, Ghaznavi-Rad E, Moslehi M, Ganji A. Wound healing performance of PCL/chitosan based electrospun nanofiber electrosprayed with curcumin loaded chitosan nanoparticles. Carbohydrate Polymers. 2021;259:117640.
25. Li L, Huang Y, Zhang Z. Expression profile of miRNAs involved in the hepatoprotective effects of curcumin against oxidative stress in Nile tilapia. Aquatic Toxicology. 2021;237:105896.
26. Munir Z, Banche G, Cavallo L, Mandras N, Roana J, Pertusio R, *et al*. Exploitation of the Antibacterial Properties of Photoactivated Curcumin as 'Green'Tool for Food Preservation. International Journal of Molecular Sciences. 2022;23(5):2600.
27. Ye MX, Li Y, Yin H, Zhang J. Curcumin: updated molecular mechanisms and intervention targets in human lung cancer. International journal of molecular sciences. 2012;13(3):3959–78.
28. Karewicz A, Bielska D, Gzyl-Malcher B, Kepczynski M, Lach R, Nowakowska M. Interaction of curcumin with lipid monolayers and liposomal bilayers. Colloids and Surfaces B: Biointerfaces. 2011;88(1):231–9.
29. Sareen R, Jain N, Rajkumari A, Dhar K. pH triggered delivery of curcumin from Eudragit-coated chitosan microspheres for inflammatory bowel disease: characterization and pharmacodynamic evaluation. Drug delivery. 2016;23(1):55–62.
30. Liu W, Zhai Y, Heng X, Che FY, Chen W, Sun D, *et al*. Oral bioavailability of curcumin: problems and advancements. Journal of drug targeting. 2016;24(8):694–702.
31. Zhang L, Wang S, Zhang M, Sun J. Nanocarriers for oral drug delivery. J Drug Target. 2013 Jul;21(6):515–27.
32. Wu X, Xu J, Huang X, Wen C. Self-microemulsifying drug delivery system improves curcumin dissolution and bioavailability. Drug Dev Ind Pharm. 2011 Jan;37(1):15–23.
33. Ma Z, Wang N, He H, Tang X. Pharmaceutical strategies of improving oral systemic bioavailability of curcumin for clinical application. Journal of Controlled Release. 2019;316:359–80.
34. Mei X, Luo X, Xu S, Xu D, Zheng Y, Xu S, *et al*. Gastroprotective effects of a new zinc(II)-curcumin complex against pylorus-ligature-induced gastric ulcer in rats. Chem Biol Interact. 2009 Oct 30;181(3):316–21.
35. Ahmed SA, Hasan MN, Bagchi D, Altass HM, Morad M, Jassas RS, *et al*. Combating Essential Metal Toxicity: Key Information from Optical Spectroscopy. ACS Omega. 2020 Jun 30;5(25):15666–72.
36. Singh DK, Jagannathan R, Khandelwal P, Abraham PM, Poddar P. In situ synthesis and surface functionalization of gold nanoparticles with curcumin and their antioxidant properties: an experimental and density functional theory investigation. Nanoscale. 2013;5(5):1882–93.
37. Katsipis G, Tsalouxidou V, Halevas E, Geromichalou E, Geromichalos G, Pantazaki AA. In vitro and in silico evaluation of the inhibitory effect of a curcumin-based oxovanadium (IV) complex on alkaline phosphatase activity and bacterial biofilm formation. Appl MicrobiolBiotechnol. 2021 Jan;105(1):147–68.
38. Sui Z, Salto R, Li J, Craik C, Ortiz de Montellano PR. Inhibition of the HIV-1 and HIV-2 proteases by curcumin and curcumin boron complexes. Bioorg Med Chem. 1993 Dec;1(6):415–22.
39. Gnanasekar N, Perianayagam J. Influence of sodium curcuminate on castor oil-induced diarrhea in rats. Vol. 36, Indian Journal of Pharmacology. Wolters Kluwer Medknow Publications; 2004. p. 177–8.
40. Rao TS, Basu N, Siddiqui HH. Anti-inflammatory activity of curcumin analogues. Indian J Med Res. 1982 Apr;75:574–8.
41. Rao TS, Basu N, Seth SD, Siddiqui HH. SOME ASPECTS OF PHARMACOLOGICAL PROFILE OF SODIUM CURCUMINATF. 1984;28(3):5.
42. Peni P, Sasri R, Silalahi IH. Synthesis of Metal–Curcumin Complex Compounds (M = Na^+, Mg^{2+}, Cu^{2+}). Jurnal Kimia Sains dan Aplikasi. 2020 Mar 31;23(3):75–82.
43. Wahyuni DSC, Artanti AN, Rinanto Y. Quantitative analysis of Curcuminoid collected from different location

in Indonesia by TLC-Densitometry and its antioxidant capacity. IOP Conf Ser: Mater Sci Eng. 2018 Apr;349:012015.
44. OECD. Test No. 420: Acute Oral Toxicity - Fixed Dose Procedure [Internet]. Paris: Organisation for Economic Co-operation and Development; 2002 [cited 2023 Aug 23]. Available from: https://www.oecd-ilibrary.org/environment/test-no-420-acute-oral-toxicity-fixed-dose-procedure_9789264070943-en
45. Fabia R, Willén R, Ar'Rajab A, Andersson R, Ahrén B, Bengmark S. Acetic acid-induced colitis in the rat: a reproducible experimental model for acute ulcerative colitis. EurSurg Res. 1992;24(4):211–25.
46. Cooper HS, Murthy SN, Shah RS, Sedergran DJ. Clinicopathologic study of dextran sulfate sodium experimental murine colitis. Lab Invest. 1993 Aug;69(2):238–49.
47. Wallace JL, Keenan CM. An orally active inhibitor of leukotriene synthesis accelerates healing in a rat model of colitis. Am J Physiol. 1990 Apr;258(4 Pt 1):G527-534.
48. Kim JJ, Shajib MdS, Manocha MM, Khan WI. Investigating Intestinal Inflammation in DSS-induced Model of IBD. JoVE. 2012 Feb 1;(60):3678.
49. MARKLUND S, MARKLUND G. Involvement of the Superoxide Anion Radical in the Autoxidation of Pyrogallol and a Convenient Assay for Superoxide Dismutase. European Journal of Biochemistry. 1974;47(3):469–74.
50. ELLMAN GL. Tissue sulfhydryl groups. Arch BiochemBiophys. 1959 May;82(1):70–7.
51. Aebi H. Catalase in vitro. Methods Enzymol. 1984;105:121–6.
52. Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem. 1979 Jun;95(2):351–8.
53. Prasad S, DuBourdieu D, Srivastava A, Kumar P, Lall R. Metal–Curcumin Complexes in Therapeutics: An Approach to Enhance Pharmacological Effects of Curcumin. International Journal of Molecular Sciences. 2021;22(13):7094.
54. Al-Rejaie SS, Abuohashish HM, Al-Enazi MM, Al-Assaf AH, Parmar MY, Ahmed MM. Protective effect of naringenin on acetic acid-induced ulcerative colitis in rats. World J Gastroenterol. 2013 Sep 14;19(34):5633–44.
55. Owusu G, Obiri DD, Ainooson GK, Osafo N, Antwi AO, Duduyemi BM, *et al*. Acetic Acid-Induced Ulcerative Colitis in Sprague Dawley Rats Is Suppressed by Hydroethanolic Extract of Cordia vignei Leaves through Reduced Serum Levels of TNF-α and IL-6. Robak T, editor. International Journal of Chronic Diseases. 2020 Feb 6;2020:8785497.
56. Yin S, Yang H, Tao Y, Wei S, Li L, Liu M, *et al*. Artesunate ameliorates DSS-induced ulcerative colitis by protecting intestinal barrier and inhibiting inflammatory response. Inflammation. 2020 Apr 1;43(2):765–76.
57. Bank S, Julsgaard M, Abed OK, Burisch J, Broder Brodersen J, Pedersen NK, *et al*. Polymorphisms in the NFkB, TNF-alpha, IL-1beta, and IL-18 pathways are associated with response to anti-TNF therapy in Danish patients with inflammatory bowel disease. Alimentary Pharmacology & Therapeutics. 2019;49(7):890–903.
58. Buer LCT, Høivik ML, Warren DJ, Medhus AW, Moum BA. Combining Anti-TNF-α and Vedolizumab in the Treatment of Inflammatory Bowel Disease: A Case Series. Inflammatory Bowel Diseases. 2018 Apr 23;24(5):997–1004.
59. Tripathi K, Feuerstein JD. New developments in ulcerative colitis: latest evidence on management, treatment, and maintenance. Drugs Context. 2019;8:212572.
60. Goyal N, Rana A, Ahlawat A, Bijjem KRV, Kumar P. Animal models of inflammatory bowel disease: a review. Inflammopharmacology. 2014;22(4):219–33.
61. El-Naggar ME, Hussein J, El-sayed SM, Youssef AM, Bana ME, Latif YA, *et al*. Protective effect of the functional yogurt based on Malva parviflora leaves extract nanoemulsion on acetic acid-induced ulcerative colitis in rats. Journal of Materials Research and Technology. 2020;9(6):14500–8.
62. Shanmugam S, Thangaraj P, Lima B dos S, Trindade GGG, Narain N, Silva AM de O e, *et al*. Protective effects of flavonoid composition rich P. subpeltata Ortega. on indomethacin induced experimental ulcerative colitis in rat models of inflammatory bowel diseases. Journal of Ethnopharmacology. 2020;248:112350.
63. Adhikari A, Basnet S, Vijayakumar S, Suhas DS, Puneeth TA, Thippeswamy BS, *et al*. Blumealacera DC., accelerates the healing of acetic acid induced ulcerative colitis in rats by regulating oxidative stress and colonic inflammation: in-vivo and in silico molecular docking experiments. Advances in Traditional Medicine. 2021 Sep 1;21(3):463–74.
64. Ahmedy OA, Ibrahim SM, Salem HH, Kandil EA. Antiulcerogenic effect of melittin via mitigating TLR4/TRAF6 mediated NF-κB and p38MAPK pathways in acetic acid-induced ulcerative colitis in mice. Chemico-Biological Interactions. 2020;331:109276.
65. Saber S, Khalil RM, Abdo WS, Nassif D, El-Ahwany E. Olmesartan ameliorates chemically-induced ulcerative colitis in rats via modulating NFκB and Nrf-2/HO-1 signaling crosstalk. Toxicology and Applied Pharmacology. 2019;364:120–32.

****